Department of Medical Oncology, Institut Jules Bordet, Rue Meylemeersch 90, Anderlecht 1070, Belgium; Université Libre de Bruxelles (ULB), Brussels, Belgium; European Organisation for Research and Treatment of Cancer, Brussel, Belgium.
European Organisation for Research and Treatment of Cancer, Brussel, Belgium; Sarah Cannon Research Institute, London, UK.
Clin Colorectal Cancer. 2022 Sep;21(3):188-197. doi: 10.1016/j.clcc.2022.04.001. Epub 2022 Apr 25.
Recently, we have witnessed impressive diagnostic and therapeutic changes for gastrointestinal cancer patients. New challenges brought by the COVID-19 pandemic have led us to re-evaluate our work priorities. Thanks to the commendable resilience of both investigators and patients, however, clinical research never stopped. In addition to conducting cutting-edge research and serving patients' needs, as EORTC Gastrointestinal Tract Cancer Group, we are committed to pursuing educational initiatives beneficial to the entire European oncology community and beyond. In this regard, we have been providing critical discussions of new data from major international meetings. In this article, we discuss results of important selected studies presented at the 2022 ASCO Gastrointestinal Cancer Symposium, putting them in perspectives and highlighting potential implications for routine practice. With the number of in-person attendees and practice-changing/informing trials presented, this meeting represented a milestone in the return to normality as well as in the fight against cancer.
最近，我们见证了胃肠道癌症患者令人瞩目的诊断和治疗变化。COVID-19 大流行带来的新挑战促使我们重新评估我们的工作重点。然而，由于调查人员和患者令人钦佩的适应能力，临床研究从未停止。除了开展前沿研究和满足患者需求外，作为 EORTC 胃肠道癌症小组，我们还致力于开展有益于整个欧洲肿瘤学界乃至更广泛领域的教育计划。在这方面，我们一直在对主要国际会议的新数据进行批判性讨论。在本文中，我们讨论了在 2022 年 ASCO 胃肠道癌症研讨会上展示的重要选定研究的结果，从不同角度进行了阐述，并强调了对常规实践的潜在影响。本次会议展示了大量的现场参会人数和改变实践/提供信息的试验，标志着癌症治疗回归常态以及抗击癌症的一个里程碑。
